EIDD-3525 is a broad-spectrum antiviral against alphavirus infection that targets the nsP4 RNA-dependent RNA polymerase
Yin, P.; Choudhary, S.; Wang, S.; Davenport, B. J.; Truong, P. M.; Sticher, Z. M.; Krueger, R.; Cruz, A. A.; Smith, M.; Kolykhalov, A. A.; Vyshenska, D.; Greninger, A. L.; Mao, S.; Natchus, M. G.; Painter, G. R.; Merits, A.; Kielian, M.; Morrison, T. E.
Show abstract
Mosquito-transmitted alphaviruses, including chikungunya (CHIKV), Mayaro, Eastern equine encephalitis, and Venezuelan equine encephalitis viruses, cause severe arthritic or neurologic disease in humans. There are currently no approved antiviral treatments against alphavirus infection. Here, we report that the purine ribonucleoside EIDD-3525 is a potent inhibitor of alphavirus replication in vitro with broad spectrum antiviral activity against the Alphavirus genus. Using a trans-replicase assay, we find that EIDD-3525 blocks alphavirus RNA replication. Mutational profiling suggests that EIDD-3525 targets the alphavirus nsP4 RNA-dependent RNA polymerase that is conserved across medically important alphaviruses. In a pre-clinical mouse model of CHIKV infection and disease, oral treatment with EIDD-3525 reduced viral tissue burdens and the severity of virus-induced disease. Collectively, our findings support the continued development of the purine ribonucleoside EIDD-3525 as an orally available antiviral therapeutic for use against a broad group of alphaviruses.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Molnupiravir inhibits Bourbon virus infection and disease-associated pathology in mice 94%
- Identification of an antiretroviral small molecule that appears to be a host-targeting inhibitor of HIV-1 assembly 94%
- Inhibition of arterivirus RNA synthesis by cyclophilin inhibitors is counteracted by mutations in replicase transmembrane subunits 93%
Similar papers in this journal
- Combinations of approved oral nucleoside analogues confer potent suppression of alphaviruses in vitro and in vivo 96%
- Bemnifosbuvir and remdesivir inhibit tick-borne encephalitis virus infection in complementary in vitro and ex vivo disease models 96%
- Ciclopirox suppresses poxvirus replication by targeting iron metabolism 93%
Similar papers in this journal
Similar papers in this journal
- Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections 95%
- Oral dosing of the nucleoside analog obeldesivir is efficacious against RSV infection in African green monkeys 94%
- Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model 93%
Similar papers in this journal
- Pan-viral protection against arboviruses by targeting inoculation site-based skin macrophages 94%
- AZD7442 demonstrates prophylactic and therapeutic efficacy in non-human primates and extended half-life in humans 93%
- Rational design of a new class of protease inhibitors for the potential treatment of coronavirus diseases 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.